ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) declined considerably to $3.80. On Mar, 27 it was announced by Barchart.com. The company has $614.13M market cap. At $3.69 target, the company’s valuation could be $18.42 million less.
ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage
A total of 2 analysts rate ZIOPHARM Oncology (NASDAQ:ZIOP) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Š¢herefore 100% are bullish. (NASDAQ:ZIOP) has 5 ratings reports on Mar 27, 2019 according to StockzIntelligence. On Thursday, November 15 the firm has “Outperform” rating by Raymond James given. On Wednesday, March 6 H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating. H.C. Wainwright has “Buy” rating and $5.5 target.
For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news published briefly go to: Nasdaq.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Ziopharm Oncology (ZIOP) Reports Q3 Loss, Lags Revenue Estimates – Nasdaq” published on November 13, 2018, “Ziopharm slips 1% after hours following release of early-stage data on gene therapy Controlled IL-12 – Seeking Alpha” on November 16, 2018, “Ziopharm and Precigen Redefine Relationships, Announce New License Agreement – GlobeNewswire” with a publish date: October 09, 2018, “Ziopharm attempts to reassure investors – Seeking Alpha” and the last “Ziopharm Oncology Promotes Dr. David Mauney to President – GlobeNewswire” with publication date: December 13, 2018.
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The company has $614.13 million market cap. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .3.97 is the P/E ratio. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.